Close Menu

CHICAGO (GenomeWeb)– A subpopulation of metastatic breast cancer patients with germline mutations in BRCA1 and BRCA2 genes had a 42 percent lower chance of progression with AstraZeneca's PARP inhibitor Lynparza (olaparib) compared to chemotherapy, a study has shown.

The randomized study presented at the American Society of Clinical Oncology's annual meeting is the first to show a PARP inhibitor extends progression-free survival in advanced breast cancer patients. It also is a sign of the expanding utility of BRCA testing in precision medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Dec
17
Sponsored by
Thermo Fisher Scientific

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.